SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-310826"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-310826" > HOX gene expression...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003722naa a2200529 4500
001oai:DiVA.org:uu-310826
003SwePub
008161220s2017 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:135217503
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3108262 URI
024a https://doi.org/10.1038/leu.2016.2222 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1352175032 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Kontro, M4 aut
2451 0a HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
264 c 2016-08-08
264 1b Springer Science and Business Media LLC,c 2017
338 a print2 rdacarrier
520 a Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. To identify robust biomarkers for BCL-2 inhibitor sensitivity, we evaluated the ex vivo sensitivity of fresh leukemic cells from 73 diagnosed and relapsed/refractory AML patients, and then comprehensively assessed whether the responses correlated to specific mutations or gene expression signatures. Compared with samples from healthy donor controls (nonsensitive) and chronic lymphocytic leukemia (CLL) patients (highly sensitive), AML samples exhibited variable responses to BCL-2 inhibition. Strongest CLL-like responses were observed in 15% of the AML patient samples, whereas 32% were resistant, and the remaining exhibited intermediate responses to venetoclax. BCL-2 inhibitor sensitivity was associated with genetic aberrations in chromatin modifiers, WT1 and IDH1/IDH2. A striking selective overexpression of specific HOXA and HOXB gene transcripts were detected in highly BCL-2 inhibitor sensitive samples. Ex vivo responses to venetoclax showed significant inverse correlation to β2-microglobulin expression and to a lesser degree to BCL-XL and BAX expression. As new therapy options for AML are urgently needed, the specific HOX gene expression pattern can potentially be used as a biomarker to identify venetoclax-sensitive AML patients for clinical trials.Leukemia advance online publication, 2 September 2016; doi:10.1038/leu.2016.222.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
700a Kumar, A4 aut
700a Majumder, M M4 aut
700a Eldfors, S4 aut
700a Parsons, A4 aut
700a Pemovska, T4 aut
700a Saarela, J4 aut
700a Yadav, B4 aut
700a Malani, D4 aut
700a Fløisand, Y4 aut
700a Höglund, Martinu Uppsala universitet,Hematologi4 aut0 (Swepub:uu)martinhl
700a Remes, K4 aut
700a Gjertsen, B T4 aut
700a Kallioniemi, Ou Karolinska Institutet4 aut
700a Wennerberg, K4 aut
700a Heckman, C A4 aut
700a Porkka, K4 aut
710a Uppsala universitetb Hematologi4 org
773t Leukemiad : Springer Science and Business Media LLCg 31:2, s. 301-309q 31:2<301-309x 0887-6924x 1476-5551
856u https://helda.helsinki.fi/bitstream/10138/178840/1/HOX_gene_expression_predicts_response.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-310826
8564 8u https://doi.org/10.1038/leu.2016.222
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:135217503

Hitta via bibliotek

  • Leukemia (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy